EMERYVILLE, Calif.--(EON: Enhanced Online News)--KineMed, Inc. (www.kinemed.com) today announced that Dr. Scott Turner, Executive Vice President of Research and Development at KineMed, Inc., will give a presentation titled “Dynamics of Lipoproteins and Cholesterol” at the 22nd Annual South East Lipid Research Conference (SELRC) http://www.selrc.org being held at the Mountain Creek Inn, located in Pine Mountain, Georgia, September 26-28, 2013.
“KineMed’s breakthroughs in combining tandem mass spectrometry with stable isotope labeling now allow unprecedented insights into the dynamics of circulating lipoproteins and lipids in humans. This has created new opportunities to identify pathways that contribute to the development and reversal of atherosclerosis”
“KineMed’s breakthroughs in combining tandem mass spectrometry with stable isotope labeling now allow unprecedented insights into the dynamics of circulating lipoproteins and lipids in humans. This has created new opportunities to identify pathways that contribute to the development and reversal of atherosclerosis,” said Dr. Scott Turner. “Patients with atherosclerosis are at risk for developing coronary heart disease (CHD), the number-one killer of both men and women in the United States. By identifying biological pathways crucial to the development and progression of atherosclerosis, KineMed is developing a suite of clinical biomarkers that can be paired with treatments for CHD and a variety of other atherosclerosis-related diseases including stroke, chronic kidney disease, and peripheral arterial disease (PAD).”
About KineMed, Inc.
KineMed is a commercial-stage company with a biomarker platform technology that is potentially transformative for drug development, personalized medicine, and wellness monitoring. KineMed's diagnostic biomarkers provide personal biology information to guide therapeutic decisions. KineMed’s biomarker platform provides dynamic molecular information through a proprietary mass spectrometric platform, representing the missing link between individuals and optimal health-related products and services. Active initiatives include prescription and non-prescription FDA-cleared diagnostic tests for personalized medicine and the next generation of drug development. These programs provide near-, mid-, and long-term revenues for KineMed from patients, payors, drug developers, and corporate partnerships.
KineMed has developed the first practically useful systems biology technology that can be used directly in humans, with applications not only in drug discovery and development, but also in clinical diagnosis, personalized medicine and therapeutic monitoring, including OTC wellness decisions. KineMed has three programs based on KineMed’s personal biology information: Rx, Dx, and Dx/Rx:
Drug discovery and development (“Rx”)
- Co-development partnerships with Pharma and Biotech to improve drug development efficiency, through R&D deals, milestone-based collaborations, and Center-of-Excellence programs
Prescription and non-prescription diagnostic tests (“Dx”)
- FDA-cleared diagnostic tests providing personalized information about key biologic processes, to allow precision medical management based on disease subtype and activity and to enable informed wellness decisions based on what is needed and what is working in each person
Diagnostic test/drug pairings (“Dx/Rx”)
- Diagnostic tests that are paired with therapeutic agents, to develop in-house drug candidates and invigorate underperforming drugs and nutraceuticals
KineMed’s biomarkers are fully translatable from animal to man across pre-clinical and clinical phases of development. This platform applies to diagnosis and management across the spectrum of diseases, including conditions involving fibrosis, neurodegeneration, muscle loss, metabolic cardiovascular or dermatologic disorders and cancer, as well as consumer wellness.
Over the past few years, KineMed has changed both textbook thought about diseases and the development path of several drug candidates. Notable accomplishments include:
- Transforming the pathogenic model of chronic lymphocytic leukemia (CLL)
- Developing the first blood-based biomarker of tissue fibrogenesis in humans
- Generating the first accurate non-invasive laboratory biomarkers of muscle mass and muscle quality in humans
- Creating the first diagnostic tests of disease-modifying processes in a neurodegenerative disease (Parkinson’s disease)
- Developing a “tachometer” of reverse cholesterol transport and metrics of plasma lipid dynamics
- Identifying new, secondary indications for drug candidates in Pharma pipelines
- Identifying new targets for drug development in several important diseases
For more information about KineMed, please visit: www.kinemed.com.